Lymphoma Clinical Trials in Philadelphia, Pennsylvania

8 studies are recruiting for lymphoma in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

   The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to <18 years of age with soma…

   Stage

   Phase 1

   Ages

   2 to 18

   Site

   The Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania

   Locations

   6 in total

   Run by

   ITM Solucin GmbH

   See if you can join NCT06441331 on ClinicalTrials.gov

2. AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

   This study is designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Research Site, Philadelphia, Pennsylvania

   Locations

   39 in total

   Run by

   AstraZeneca

   See if you can join NCT06137144 on ClinicalTrials.gov

3. A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

   The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Thomas Jefferson University, Philadelphia, Pennsylvania

   Locations

   18 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT06624085 on ClinicalTrials.gov

4. A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

   Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor k…

   Stage

   Phase 1

   Ages

   Up to 25

   Site

   Children's Hospital of Philadelphia-Center for Childhood Cancer Research, Philadelphia, Pennsylvania

   Locations

   68 in total

   Run by

   Turning Point Therapeutics, Inc.

   See if you can join NCT04094610 on ClinicalTrials.gov

5. TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

   The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   14 in total

   Run by

   Treeline Biosciences, Inc.

   See if you can join NCT07082803 on ClinicalTrials.gov

6. A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

   The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   40 in total

   Run by

   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

   See if you can join NCT07015242 on ClinicalTrials.gov

7. Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

   The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, n…

   Stage

   Not phased

   Ages

   0 to 38

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Locations

   5 in total

   Run by

   Children's Hospital Medical Center, Cincinnati

   See if you can join NCT06131801 on ClinicalTrials.gov

8. A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer

   This is a first-in-human, phase I, open-label, non-randomized dose-escalation and dose-expansion study with the primary objective to determine the safety profile of small molecule, mitochondrial-targeted Hsp90 inhibitor, gamitrinib, including identification of dose-limiting toxicities (DLT) and max…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Fox Chase Cancer Center, Philadelphia, Pennsylvania

   Run by

   Fox Chase Cancer Center

   See if you can join NCT04827810 on ClinicalTrials.gov